NCT01046422 - Safety Study of BMS-770767 in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Diabetes Type 2

Interventions

DRUG

BMS-770767

Capsule, Oral, 15mg, Active, Daily, 28 days

DRUG

BMS-770767

Capsule, Oral, 50mg, Active, Daily, 28 days

DRUG

BMS-770767

Capsule, Oral, 150mg, Active, Daily, 28 days

DRUG

BMS-770767

Capsule, Oral, 50mg BID, Active, Daily, 28 days

DRUG

Placebo

Capsule, Oral, 0mg, Daily, 28 days

DRUG

Metformin

Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days

Trial Locations (18)

3220

Local Institution, Geelong

4131

Local Institution, Meadowbrook

4510

Local Institution, Caboolture

5041

Local Institution, Daw Park

6009

Local Institution, Nedlands

89101

Nevada Alliance Against Diabetes, Las Vegas

90717

Marina Raikhel, Md, Lomita

R3P 1R9

Local Institution, Winnipeg

A1N 1W7

Local Institution, Mount Pearl

L6T 3J1

Local Institution, Brampton

M4G 3E8

Local Institution, Toronto

C1A 5Y9

Local Institution, Charlottetown

J2B 7T1

Local Institution, Drummondville

H8S 2E4

Local Institution, Lachine

H7T 2P5

Local Institution, Laval

H3J 2V5

Local Institution, Montreal

405-760

Local Institution, Incheon

443-721

Local Institution, Suwon